The University of Pittsburgh Dorothy P. and Richard P. Simmons Center for interstitial Lung disease
Founded in 2001 thanks to the generosity of the Simmons family, The Dorothy P. and Richard P. Simmons Center for Interstitial Lung Disease provides:
- State-of-the-art care for people with interstitial lung disease (ILD) that is comprehensive and compassionate.
- International leadership in research on lung inflammation and fibrosis, promoting the translation of scientific discoveries into new treatments for patients with these lung disorders.
- A complete resource for the education of patients and their families regarding ILD and its impact on their lifestyle.
- Patient-friendly advice and support for people with idiopathic pulmonary fibrosis (IPF).
About Pulmonary Fibrosis
Pulmonary Fibrosis (PF) is a lung disorder characterized by a progressive scarring – known as fibrosis – and deterioration of the lungs, which slowly robs its victims of their ability to breathe. Sometimes PF can be linked to a particular cause, such as certain environmental exposures, chemotherapy or radiation therapy, residual infection, or autoimmune diseases such as scleroderma or rheumatoid arthritis. However, in many instances, no known cause can be established. When this is the case, it is called idiopathic pulmonary fibrosis (IPF).
What You Need to Know About Pulmonary Fibrosis
IPF affects about 200,000 people in the United States, with about 40,000 new cases estimated to occur annually.
· PF is a relentless, incurable lung disease with no known cause, no cure, and no FDA approved treatment.
· Patients with PF typically experience shortness of breath and a dry cough, which become progressively worse and debilitating.
· From time of diagnosis, patients with PF are estimated to live a few years, a few months or a few weeks. The average PF patient lives just 2.8 years.
· Every 11 minutes a new patient is diagnosed with PF - the same number as breast cancer.